The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

Table 2 Severity and HIT-6 Responder Analysis

Proportion of severity responders, among headache-day frequency non-responders ^a
	OnabotulinumtoxinA/ OnabotulinumtoxinA n = 285	Placebo / OnabotulinumtoxinA n = 360	P-value
Week 24	41.1%	31.4%	0.011
Week 56	64.6%	65.6%	0.792
Proportion of HIT-6 responders, among severity responders ^b
	OnabotulinumtoxinA/ OnabotulinumtoxinA n = 246	Placebo / OnabotulinumtoxinA n = 161	P-value
Week 24	62.2%	43.5%	<0.001
Week 56	74.4%	72.0%	0.601

HIT-6 6-item Headache Impact Test
^aPatients with severity response (≥1-grade improvement from baseline in severity), among patients with <50% reduction from baseline in headache-day frequency at week 24
^bPatients with a HIT-6 response (≥5-point improvement from baseline), among patients with ≥1-grade reduction from baseline in headache-day severity at week 24

ISSN: 1129-2377